{"entity":{"id":"nct04891198","kind":"trial","name":"ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 2 trial of Envafolimab in advanced solid tumours, run by 3D Medicines (Sichuan) Co., Ltd., now recruiting.","summary":"ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors is a phase 2 interventional study registered as NCT04891198 by 3D Medicines (Sichuan) Co., Ltd., with 126 participants planned, started 2021-08-06 and due to reach its primary completion in 2027-08-30. Interventions recorded: Envafolimab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04891198","url":"https://clinicaltrials.gov/study/NCT04891198"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["envafolimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04891198","phase":"2","setting":"An Open, Single-arm, Multi-center Phase II Clinical Study of ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors","sponsor":"3D Medicines (Sichuan) Co., Ltd.","enrolled":126,"outcomes":[]},"route":"/trials/nct04891198/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"envafolimab","kind":"drug","name":"Envafolimab","route":"/drugs/envafolimab/"}]}}